RBDCOV, towards a new COVID-19 vaccine for children, adolescents and people with immunocompromising conditions using a recombinant protein.

RBDCOV will test the efficacy, tolerability, and safety of the vaccine against the variants of COVID19

What is RBDCOV ​

RBDCOV aims to test the efficacy, tolerability, and safety of the HIPRA vaccine for COVID-19. HIPRA's vaccine is an adjuvanted recombinant protein vaccine, based on a receptor binding domain (RBD) fusion heterodimer against SARS-CoV-2.

The initiative is an innovative vaccine-focused research project that brings together the expertise of a number of European organisations and companies that work in vaccine design and manufacturing, clinical, trials and research, vaccine distribution and commercialisation, regulatory aspects, stakeholder involvement, trial and patient community perspective.

 COVID-19 has been categorised by the WHO as a pandemic. Apart from it being a global health crisis some of the containment measures adopted by different countries have incurred inevitable socio-economic implications.



How does the vaccine work


Choose a country:

Recruitment forms

Don't miss the opportunity to be part of the solution!

Participate in the clinical trial and helps to fulfil the purpose of the project: to offer a new tool to control the pandemic at short-medium and long term, and to manufacture and test the first recombinant protein-based vaccine to be authorised in Europe

Our partners


Press Office

Contact us for general information

Susana Garayoa sgarayoa@zabala.eu
Phone number: M (+32) 484 61 91 64

Nora Franco nfranco@zabala.es
Phone number: M (+34) 673 005 759